Study of Effects of Probiotic Lactobacilli in Preventing Major Complications in Patients of Liver Cirrhosis
|
|
- Willa Pitts
- 8 years ago
- Views:
Transcription
1 Research Article Study of Effects of Probiotic Lactobacilli in Preventing Major Complications in Patients of Liver Cirrhosis RR. Pawar*, ML. Pardeshi and BB. Ghongane Department of Pharmacology, B.J. Medical College and Sassoon General Hospital, Station Road, Pune, Maharastra, India. ABSTRACT The aim was to evaluate the effects of probiotic lactobacilli on incidence of major complications, hospital admissions and mortality in patients of liver cirrhosis. In this randomized, double-blind, placebo-controlled study, 65 patients with liver cirrhosis received either lactobacilli (n = 34) or placebo (n =31) for 6 months. They were monitored for complications (hepatic encephalopathy, variceal bleeding, and spontaneous bacterial peritonitis), hospital admissions and deaths, if any. Serum bilirubin, SGPT, SGOT, serum proteins, blood urea, Sr.creatinine and plasma-ammonia were done at each visits. Probiotic lactobacilli significantly reduced the incidence of hepatic encephalopathy and hospital admissions. There was significant decrease in plasma-ammonia in lactobacilli treated group. Though the serum bilirubin levels worsened in both the groups, this worsening was significantly less in the lactobacilli treated group as against placebo. The present study suggests that the use of probiotic lactobacilli is beneficial in prevention of major complications in patients with liver cirrhosis. Key Words: Liver cirrhosis, Lactobacilli, Hepatic encephalopathy, Ammonia. INTRODUCTION Cirrhosis is a pathologically defined entity that is associated with a spectrum of characteristic clinical manifestations. The cardinal pathologic features reflect irreversible chronic injury of the hepatic parenchyma and include extensive fibrosis in association with the formation of regenerative nodules 1. Colonic bacteria clearly play a major role in the pathogenesis of major complications in patients with liver cirrhosis. By producing ammonia and endotoxins they can cause hepatic encephalopathy and their translocation from the gut to the peritoneal cavity is the major mechanism for spontaneous bacterial peritonitis 2. Probiotics are "live microorganisms which when administered in adequate amounts confer a health benefit on the host." They work a number of ways including competitive exclusion, production of bacteriocins and lowering of gut ph 3. Probiotics have been used successfully to alter the gut flora in many clinical conditions where growth and localization of non pathogenic bacteria replaces the pathogenic bacteria in the intestine. Silvia Wilson Gratz in her review article about role of probiotics in liver disease stated that, in the liver health, the main benefits of probiotics might occur through preventing the production and/or uptake of lipopolysaccharides in the gut, and therefore reducing levels of low-grade inflammation 4. Loguercio et al used the phrase gut liver axis and suggested that the microflora might affect the liver and be cofactor in etiology of chronic liver damage. This could happen via modulating chronic damage by ethanol or by contributing to complications such as encephalopathy (production of ammonia, ethanol, acetaldehyde, phenols, endotoxin, and benzodiazepines) 5. According to the results of a randomized trial published in the May issue of Hepatology, symbiotic modulation of gut flora or use of fermentable fiber is effective in the treatment of minimal hepatic encephalopathy (MHE) and may be an alternative to lactulose 6. However there is need of a study to determine whether the probiotics have any role in the prevention of major complications of liver cirrhosis. Hence the present study was undertaken for the same. MATERIALS AND METHODS This study was a prospective, randomised, doubleblind, placebo-controlled, single centre study. Vol. 3 (1) Jan Mar
2 The study was conducted on patients of liver cirrhosis attending Gastroenterology unit of a tertiary health care centre. The study protocol was approved by the Institutional Ethics Committee. Patients who were admitted for liver cirrhosis in the hospital or who developed any complication earlier but cured at the time of recruitment were included in the present study. Diagnosis of liver cirrhosis was confirmed on USG. Written informed consent (translated in Marathi) was obtained from each patient in the beginning of the study. Only those patients who fulfilled the eligibility criteria were included in the study. The patients were randomized into 2 groups by computer randomization The drugs were supplied by Unique Biotech, Chennai. All patients also received the routine treatment that was given to them in hospital, i.e. diuretics, antibiotics and lactulose etc. All the investigations were repeated at 3 months and six months. Patients were followed up for 6 months to see if they develop any complication like hepatic encephalopathy, spontaneous bacterial peritonitis, variceal bleeding etc. The detailed data was entered into the Microsoft excel sheet and subsequently analyzed by using appropriate statistical tests. RESULTS A total 65 patients were enrolled in the study. Out of these 51 (78.5%) completed the study. 14 patients could not complete the study. Of these, 2 patients in lactobacilli group and 2 patients in placebo group were excluded at visit 2, because they turned towards alcoholism. Also 2 patients in the placebo group were excluded from trial at V3 for the same reason. 5 patients died during the study period. 2 patients in lactobacilli group and 1 patient in placebo group did not come for follow up after V1. The data was analyzed by both intention to treat and per protocol approach. Both approaches showed comparable results. The data presented here is by the intention to treat method. The total data available for analysis was of 65 patients. Out of 65 patients, 62 were male and 3 were female. Sex distribution of patients in two groups was even (Table: 2). Average age of patients in lactobacilli group was years SD with a range of 29 to 53 years while that of in placebo group years ± 5.22 SD with range of 30 to 54 years. Average weight in lactobacilli group was kg ± 4.96 SD with a range of 35 to 55 kg, whereas average weight in placebo group was kg ± 4.64 SD with range of 36 to 67 kg (Table: 2). All the base-line investigations were comparable in both the groups (Table: 3). Incidence of Complications of Cirrhosis Primary efficacy variable was incidence of complications of cirrhosis in two groups during the period of six months. As seen in fig: 1; Out of 34 patients in lactobacilli group, 3 patients developed hepatic encephalopathy as complication in treatment period; which is significantly less than placebo group, in which out of 31 patients, 9 patients developed hepatic encephalopathy. Out of 34 patients in lactobacilli group, 4 patients suffered from variceal bleeding, 5 patients developed SBP and 4 patients developed other complications; which is not significantly different than placebo group, in which out of 31 patients 5 patients suffered from variceal bleeding, 3 patients developed SBP and 6 patients developed other complications. Number of Episodes of Hospital Admissions and Death In lactobacilli group significantly less number of episodes of hospital admissions were required (n = 18, i.e admissions/patient) as compared to the placebo group (n= 27, i.e admissions/patient) during the treatment period of 6 months (Table: 4). 3 patients died in lactobacilli group whereas 2 patients died in placebo group (Table: 4). There is no difference in two groups when number of deaths was compared. Plasma Ammonia Levels Plasma ammonia levels decreased (from to ) in the lactobacilli group during the study period (Fig. 3). The decrease was statistically significant at V2 and V3 as compared to V1. However plasma ammonia levels increased (from to ) in placebo group during the study period. The increase was statistically significant at V2 and V3 as compared to V1, this increase was significantly more at V3 than at V2. When the intergroup analysis was done, plasma ammonia level in lactobacilli group was significantly less than that of placebo group at V2 and V3. Serum bilirubin levels Serum bilirubin levels increased in both the groups during the study period. This increase in Sr. bilirubin levels was significant in both the groups at the last visit (V3) as compared to V1. The lactobacilli group showed increase from to , during the period of 6 months whereas the placebo Vol. 3 (1) Jan Mar
3 group showed increase from to during the same period (Fig. 4). When the intergroup analysis was done, increase in Sr. Bilirubin level in lactobacilli group was significantly less than that of placebo group. When other liver function parameters like serum SGPT, SGOT, ALP, proteins, A/G ratio etc were compared in two groups, no significant difference was observed. All these parameters were significantly increased in both the treatment groups during the period of 6 months. DISCUSSION The distribution of intestinal microflora in healthy adults is relatively stable, unless disrupted by disease or medications. Both animal and clinical studies have shown that patients with liver cirrhosis have varying degrees of intestinal microflora imbalance, as shown by the changes in the counts of Bifidobacterium, Bacterioides, Enterobacter and yeasts 7, 8. In the present study, use of lactobacilli sporogenes in the patients of liver cirrhosis was studied. It was found that the treatment with lactobacilli significantly reduced the incidence of hepatic encephalopathy as compared to placebo over the period of six months. There was significant reduction in hospital admissions in patients taking lactobacilli as compared to placebo. However there was no significant reduction in the incidence of other complications like variceal bleeding, spontaneous bacterial peritonitis, hepatorenal syndrome etc. Also there was no significant difference in the number of deaths in two groups. It was also found that there was significant reduction in the plasma ammonia levels in lactobacilli group as compared to placebo group. Similarly, increase (worsening) in serum bilirubin levels was significantly less in lactobacilli group as compared to placebo group. However there was no significant improvement in other parameters like serum SGPT, SGOT, ALP, proteins, A/G ratio etc in both the groups. To our best knowledge, this was the first study with lactobacilli which studied effect of lactobacilli on all the major complications of liver cirrhosis without altering patients current medications. However, there were limitations like small sample size and shorter duration of follow up. Further studies should focus to evaluate the effect of different probiotics at different grades of cirrhosis using larger sample size. Also cost benefit analysis should be done to see whether probiotics are cheaper and effective alternative to current therapy. Table 1: Drugs used in the study Group No. of Patients Drugs Formulation, Dose, Frequency And Duration of Administeration Lactobacilli 34 Lactobacilli sporogenes Cap. Lactobacilli 2 billion CFU/ capsule, 2 cap. twice daily for 6 months. Placebo 31 Placebo Placebo capsules, 2 cap. twice daily for 6 months. Table 2: Demographic and Baseline Characteristics Criteria (n=34) (n=31) Average age in years [Mean ± SD] ± ± 5.22 Sex (M:F) 32/2 30/1 Average Weight (kg) [Mean ± SD] ± ± 9.26 No. of patients with h/o alcoholism (%) 27 (79.41) 26 (83.87) No. of patient taking Lactulose (%) 34 (100) 31 (100) No. of patients taking antibiotics (%) 23 (67.65) 27 (87.1) Vol. 3 (1) Jan Mar
4 Table 3: Comparison of Baseline (V1) Investigations in Two Groups Investigations Lactobacill Group (n=34) Placebo Group (n= 31) Sr. Bilirubin (mg/dl) Sr. SGPT (IU/L) Sr. SGOT (IU/L) Sr. ALP (IU/L) Sr. Albumin (gm/dl) 2.71 ± ± 0.45 A/G Ratio 0.96 ± ± 0.14 Blood Urea (mg/dl) Sr. Creatinine (mg/dl) Plasma Ammonia (µg/dl) [Mean ± SD] Table 4: Hospital admissions and number of deaths Total Total Criteria admissions (Admissions/patient, admissions (Admissions/patient, p value Mean + SD) Mean + SD) Number of episodes of hospital admissions 18 ( ) 27 ( ) 0.043* Number of deaths Day 0 (V1) Start of study: - History and examinations Investigation s:- LFT, RFT, Pl. Ammonia, Drugs 3 months (V2) All investigation s Drugs Inquiry about complication s Fig. 1: Study Design 6 months (V3) Number of complication s Hospital admissions PL. Ammonia, L FT, RFT,. Deaths if any Analysis Vol. 3 (1) Jan Mar
5 30 % * *: p value < 0.05 Fig. 2: Incidences of Complications of Cirrhosis 200 Plasma Ammonia in µg/dl V1 V2 V3 V1: Visit 1 V2: Visit 2 V3: Visit 3 *:p value < 0.05 **: p value < Fig. 3: Plasma Ammonia Levels Vol. 3 (1) Jan Mar
6 3 Serum Bilirubin in mg/dl V1 V2 V3 * V1: Visit 1 V2: Visit 2 V3: Visit 3 *:p value < 0.05 Fig. 4: Serum Bilirubin Levels CONCLUSION From the present study, it can be concluded that Probiotic lactobacilli showed significant reduction in the incidence of hepatic encephalopathy as compared to placebo during the treatment period of 6 months. Also there was significant reduction in the plasma ammonia levels in the lactobacilli treated patients as compared to placebo treated patients during the study period of 6 months. The increase was significantly less in the lactobacilli group as compared to placebo group. REFERENCES 1. Raymond D. Chung. Cirrhosis and its complications. In: Fauci, Braunwald et al editors. Harrison s principles of internal medicine. 16th ed. New York (USA): McGraw-Hill Publications; 2005: Suvarna VC and Boby VU. Probiotics in human health: A current assessment. Current science. 2005;88(11): David Pereg. Probiotics for patients with compensated liver cirrhosis: A double-blind placebo-controlled study. Nutrition. Published online Available from: (Accessed 10 Oct 2010). 4. Silvia Wilson Gratz et al. Probiotics and gut health: A special focus on liver diseases. World J Gastroenterol. 2010;16(4): Loguercio C, De Simone T, Federico A et al. Gutliver axis: a new point of attack to treat chronic liver damage? Am J Gastroenterol 2002;97: Liu Q, Duan ZP, Hada K et al. Synbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis. Hepatology. 2004;39(5): Chen H, Chen GM, Yan H et al. A preliminary study on the change of intestinal microflora in patients with posthepatic cirrhosis. Chin J Dig. 1995; 15: Hua J, Li JQ, Zeng MD et al. A study of intestinal flora in patients with cirrhosis. Chin J Hepatol. 1998;6: Vol. 3 (1) Jan Mar
Oral Zinc Supplementation as an Adjunct Therapy in the Management of Hepatic Encephalopathy: A Randomized Controlled Trial
Oral Zinc Supplementation as an Adjunct Therapy in the Management of Hepatic Encephalopathy: A Randomized Controlled Trial Marcus R. Pereira A. Study Purpose Hepatic encephalopathy is a common complication
More informationEvaluation and Prognosis of Patients with Cirrhosis
Evaluation and Prognosis of Patients with Cirrhosis Marion G. Peters, MD John V. Carbone, MD, Endowed Chair Professor of Medicine Chief of Hepatology Research University of California San Francisco Recorded
More informationCirrhosis and HCV. Jonathan Israel M.D.
Cirrhosis and HCV Jonathan Israel M.D. Outline Relationship of fibrosis and cirrhosisprevalence and epidemiology. Sequelae of cirrhosis Diagnosis of cirrhosis Effect of cirrhosis on efficacy of treatment
More informationPresented by: Jean Yoo-Campbell, Matthew Konerman, Monica Konerman, Jean Yoo Campbell, Christian Gocke, Eunpi Cho Donald Lynch
Bass N.M., et. al. N Engl J Med 2010; 362:1071-1081 Presented by: Jean Yoo-Campbell, Matthew Konerman, Monica Konerman, Jean Yoo Campbell, Christian Gocke, Eunpi Cho Donald Lynch Faculty Advisor: Dr. Fred
More informationMANAGEMENT OF LIVER CIRRHOSIS
MANAGEMENT OF LIVER CIRRHOSIS Information Leaflet Your Health. Our Priority. Page 2 of 6 What is cirrhosis? Cirrhosis is a result of long-term, continuous damage to the liver and may be due to many different
More informationLamivudine for Patients with hronic Hepatitis B and Advanced Liver Disease. From : New England Journal of Medicine
Lamivudine for Patients with hronic Hepatitis B and Advanced Liver Disease From : New England Journal of Medicine Volume 351:1521-1531, Number 15, Oct 7, 2004 馬 偕 紀 念 醫 院 一 般 內 科, 肝 膽 腸 胃 科 新 竹 分 院 陳 重
More informationPEER REVIEW HISTORY ARTICLE DETAILS VERSION 1 - REVIEW
PEER REVIEW HISTORY BMJ Open publishes all reviews undertaken for accepted manuscripts. Reviewers are asked to complete a checklist review form (http://bmjopen.bmj.com/site/about/resources/checklist.pdf)
More informationHuman Clinical Study for Free Testosterone & Muscle Mass Boosting
Human Clinical Study for Free Testosterone & Muscle Mass Boosting GE Nutrients, Inc. 920 E. Orangethorpe Avenue, Suite B Anaheim, California 92801, USA Phone: +1-714-870-8723 Fax: +1-732-875-0306 Contact
More informationProbiotics for the Treatment of Adult Gastrointestinal Disorders
Probiotics for the Treatment of Adult Gastrointestinal Disorders Darren M. Brenner, M.D. Division of Gastroenterology Northwestern University, Feinberg School of Medicine Chicago, Illinois What are Probiotics?
More informationAfter the Cure: Long-Term Management of HCV Liver Disease Norah A. Terrault, MD, MPH
After the Cure: Long-Term Management of HCV Liver Disease Norah A. Terrault, MD, MPH Professor of Medicine Department of Gastroenterology Director, Viral Hepatitis Center University of California San Francisco
More informationNUTRITION IN LIVER DISEASES
NUTRITION IN LIVER DISEASES 1. HEPATITIS: Definition: - Viral inflammation of liver cells. Types: a. HAV& HEV, transmitted by fecal-oral route. b. HBV & HCV, transmitted by blood and body fluids. c. HDV
More informationManagement of hepatitis C: pre- and post-liver transplantation. Piyawat Komolmit Bangkok
Management of hepatitis C: pre- and post-liver transplantation Piyawat Komolmit Bangkok Liver transplantation and CHC Cirrhosis secondary to HCV is the leading cause of liver transplantation in the US
More informationDeveloping Innovative Therapeutics for People with Orphan Liver Disease
Developing Innovative Therapeutics for People with Orphan Liver Disease PIPELINE PROGRESS AND FIRST QUARTER 2015 EARNINGS UPDATE NASDAQ: OCRX Forward-Looking Statements Certain statements in this presentation
More informationLiver Diseases. An Essential Guide for Nurses and Health Care Professionals
Brochure More information from http://www.researchandmarkets.com/reports/1047385/ Liver Diseases. An Essential Guide for Nurses and Health Care Professionals Description: Liver disease is a rapidly growing
More informationAcute on Chronic Liver Failure: Current Concepts. Disclosures
Acute on Chronic Liver Failure: Current Concepts Vandana Khungar, MD MSc Assistant Professor of Medicine University of Pennsylvania, Perelman School of Medicine September 20, 2015 None to declare Disclosures
More informationNP/PA Clinical Hepatology Fellowship Summary of Year-Long Curriculum
OVERVIEW OF THE FELLOWSHIP The goal of the AASLD NP/PA Fellowship is to provide a 1-year postgraduate hepatology training program for nurse practitioners and physician assistants in a clinical outpatient
More informationESCMID Online Lecture Library. by author
Do statins improve outcomes of patients with sepsis and pneumonia? Jordi Carratalà Department of Infectious Diseases Statins for sepsis & community-acquired pneumonia Sepsis and CAP are major healthcare
More informationFREEDOM C: A 16-Week, International, Multicenter, Double-Blind, Randomized, Placebo-Controlled Comparison of the Efficacy and Safety of Oral UT-15C
FREEDOM C: A 16-Week, International, Multicenter, Double-Blind, Randomized, Placebo-Controlled Comparison of the Efficacy and Safety of Oral UT-15C SR in Combination with an ERA and/or a PDE-5 Inhibitor
More informationPrecipitating Factors of Hepatic Encephalopathy
Original Article Precipitating Factors of Hepatic Encephalopathy Mohammad Tariq,* Saleem Iqbal,** Naji ullah Khan,* Rabia Basri*** From Department of Medicine, Khyber Teaching Hospital, Peshawar. *Post
More informationPREVENTION OF HCC BY HEPATITIS C TREATMENT. Morris Sherman University of Toronto
PREVENTION OF HCC BY HEPATITIS C TREATMENT Morris Sherman University of Toronto Pathogenesis of HCC in chronic hepatitis C Injury cirrhosis HCC Injury cirrhosis HCC Time The Ideal Study Prospective randomized
More informationHepatic Encephalopathy, Hyperammonemia, and Current Treatment in ICU Room
Hepatic Encephalopathy, Hyperammonemia, and Current Treatment in ICU Room Assoc.Prof. Chan Sovandy Chairman by : Prof.So Saphy and Assoc Prof, Kim chhoung Hepatic Encephalopathy Hepatic (portal systemic
More informationA 55 year old man with cirrhosis due to chronic hepatitis C (CHC) genotype 3a is referred for liver transplantation.
A 55 year old man with cirrhosis due to chronic hepatitis C (CHC) genotype 3a is referred for liver transplantation. Three years ago he was treated with 24 weeks of peginterferon alfa-2a (180 µg/wk, PEGIFN)
More informationLiver Failure. Nora Aziz. www.3bv.org. Bones, Brains & Blood Vessels
Liver Failure Nora Aziz www.3bv.org Bones, Brains & Blood Vessels Severe deterioration in liver function Looses ability to regenerate/repair decompensated Liver extensively damaged before it fails Equal
More informationThe Role of Probiotic in Patient with Minimal Hepatic Encephalopathy: An Evidence Based Case Report
The Role of Probiotic in Patient with Minimal Hepatic Encephalopathy: An Evidence Based Case Report Author dr. M. Adi Firmansyah NPM: 0806484692 Supervisor dr. Andri S. Sulaiman, SpPD-KGEH Department of
More informationProbiotics Prevent Hepatic Encephalopathy in Patients with Cirrhosis: a Randomized Controlled Trial
Accepted Manuscript Probiotics Prevent Hepatic Encephalopathy in Patients with Cirrhosis: a Randomized Controlled Trial Manish Kumar Lunia, Barjesh Chander Sharma, Praveen Sharma, Sanjeev Sachdeva, Siddharth
More information{ Rifaximin versus Nonabsorbable Disaccharides for the Treatment of Hepatic Encephalopathy: A Meta Analysis}
{ Rifaximin versus Nonabsorbable Disaccharides for the Treatment of Hepatic Encephalopathy: A Meta Analysis} {Dong Wu, Shu-Mei Wu, Jie Lu, Ying-Qun Zhou, Ling Xu, and Chuan-Yong Guo} Noor Al-Hakami, Pharm
More informationMedical management of CHF: A New Class of Medication. Al Timothy, M.D. Cardiovascular Institute of the South
Medical management of CHF: A New Class of Medication Al Timothy, M.D. Cardiovascular Institute of the South Disclosures Speakers Bureau for Amgen Background Chronic systolic congestive heart failure remains
More informationrifaximin 550mg film-coated tablets (Targaxan ) SMC No. (893/13) Norgine Pharmaceuticals Ltd
rifaximin 550mg film-coated tablets (Targaxan ) SMC No. (893/13) Norgine Pharmaceuticals Ltd 09 August 2013 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and
More informationOmega-3 fatty acids improve the diagnosis-related clinical outcome. Critical Care Medicine April 2006;34(4):972-9
Omega-3 fatty acids improve the diagnosis-related clinical outcome 1 Critical Care Medicine April 2006;34(4):972-9 Volume 34(4), April 2006, pp 972-979 Heller, Axel R. MD, PhD; Rössler, Susann; Litz, Rainer
More informationActive centers: 2. Number of patients/subjects: Planned: 20 Randomized: Treated: 20 Evaluated: Efficacy: 13 Safety: 20
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: sanofi-aventis ClinialTrials.gov
More informationEconomic Impact of Treatment Options for Hepatic Encephalopathy
Economic Impact of Treatment Options for Hepatic Encephalopathy Carroll B. Leevy, M.D. 1 ABSTRACT Complications of chronic liver disease, such as hepatic encephalopathy (HE), can have a substantial impact
More informationEnd Stage Liver Disease: What is New? Marion Peters MD UCSF Berlin 2012
End Stage Liver Disease: What is New? Marion Peters MD UCSF Berlin 2012 Natural History of ESLD Increasing liver fibrosis Development of HCC Chronic liver disease Compensated cirrhosis Decompensated cirrhosis
More informationa series of fact sheets written by experts in the field of liver disease HCV DISEASE PROGRESSION
www.hcvadvocate.org HCSP FACT SHEET Symptoms & Complications of Cirrhosis Foreword After many years of infection with hepatitis C the liver can become severely scarred. The process starts with inflammation
More informationCOMPLICATIONS OF CIRRHOSIS COMPLICATIONS OF CIRRHOSIS OBSERVATIONS OF AN AGING HEPATOLOGIST. Philip C. Delich, M.D.
1 COMPLICATIONS OF CIRRHOSIS OBSERVATIONS OF AN AGING HEPATOLOGIST COMPLICATIONS OF CIRRHOSIS Philip C. Delich, M.D. Faculty Disclosure Dr. Delich has indicated that he does not have any relevant financial
More informationGruppo di lavoro: Malattie Tromboemboliche
Gruppo di lavoro: Malattie Tromboemboliche 2381 Soluble Recombinant Thrombomodulin Ameliorates Hematological Malignancy-Induced Disseminated Intravascular Coagulation More Promptly Than Conventional Anticoagulant
More informationThe State of the Liver in the Adult Patient after Fontan Palliation
The State of the Liver in the Adult Patient after Fontan Palliation Fred Wu, M.D. Boston Adult Congenital Heart Service Boston Children s Hospital/Brigham & Women s Hospital 7 th National Adult Congenital
More informationApproach to Abnormal Liver Tests
Approach to Abnormal Liver Tests Naga P. Chalasani, MD, FACG Professor of Medicine and Cellular & Integrative Physiology Director, Division of Gastroenterology and Hepatology Indiana University School
More informationboceprevir 200mg capsule (Victrelis ) Treatment experienced patients SMC No. (722/11) Merck, Sharpe and Dohme Ltd
boceprevir 200mg capsule (Victrelis ) Treatment experienced patients SMC No. (722/11) Merck, Sharpe and Dohme Ltd 09 September 2011 The Scottish Medicines Consortium (SMC) has completed its assessment
More informationClostridium Difficile Colitis. Presented by Mark Skains August 2003
Clostridium Difficile Colitis Presented by Mark Skains August 2003 What is Clostridium Difficile Gram positive rod Produces spores (hang out in diverticula) Forms Endotoxin A + B which cause diarrhea.
More informationPatterns of abnormal LFTs and their differential diagnosis
Patterns of abnormal LFTs and their differential diagnosis Professor Matthew Cramp South West Liver Unit and Peninsula Schools of Medicine and Dentistry, Plymouth Summary liver function / liver function
More informationLIVER FUNCTION TESTS AND STATINS
LIVER FUNCTION TESTS AND STATINS Philippe J. Zamor and Mark W. Russo Current Opinion in Cardiology 2011,26:338 341 SUMMARY Purpose of review: To discuss recent data on statins in patients with elevated
More informationThe Clinical Trials Process an educated patient s guide
The Clinical Trials Process an educated patient s guide Gwen L. Nichols, MD Site Head, Oncology Roche TCRC, Translational and Clinical Research Center New York DISCLAIMER I am an employee of Hoffmann-
More informationTherapy of decompensated cirrhosis Pre-transplant for HBV and HCV
Therapy of decompensated cirrhosis Pre-transplant for HBV and HCV Universitätsklinikum Leipzig Thomas Berg Sektion Hepatologie Klinik und Poliklinik für Gastroenterologie und Rheumatologie Leber- und Studienzentrum
More informationJune 11, 2015 Tim Halterman
June 11, 2015 Tim Halterman Defini&on Histologic change + loss of liver function Derives from Greek word kirrhos meaning yellow, tawny First named by Rene Laennec in 1819 Laennec s cirrhosis=alcoholic
More informationHEPATOLOGY CLERKSHIP
College of Osteopathic Medicine HEPATOLOGY CLERKSHIP Office for Clinical Affairs 515-271-1629 FAX 515-271-1727 Elective Rotation General Description This elective rotation is a four (4) week introductory,
More informationDRUG UTILIZATION EVALUATION OF ANTIHYPERTENSIVE DRUGS IN DIABETIC PATIENTS WITH CKD
WORLD JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES Elhami et al. SJIF Impact Factor 5.210 Volume 4, Issue 11, 1159-1166 Research Article ISSN 2278 4357 DRUG UTILIZATION EVALUATION OF ANTIHYPERTENSIVE
More informationThe most serious symptoms of this stage are:
The Natural Progression of Hepatitis C The natural history of hepatitis C looks at the likely outcomes for people infected with the virus if there is no medical intervention. However, the process of trying
More informationTHE INTERNET STROKE CENTER PRESENTATIONS AND DISCUSSIONS ON STROKE MANAGEMENT
THE INTERNET STROKE CENTER PRESENTATIONS AND DISCUSSIONS ON STROKE MANAGEMENT Stroke Prevention in Atrial Fibrillation Gregory Albers, M.D. Director Stanford Stroke Center Professor of Neurology and Neurological
More informationCharacterisation of co-morbidities in patients with alcoholic liver disease and engaging them in treatment.
Characterisation of co-morbidities in patients with alcoholic liver disease and engaging them in treatment. Khairunnessa Rahman, Dheeraj Shukla, Leigh Dahlenburg, Andrew Bailey, Robert Gribble, Paul Haber
More informationLIVER FUNCTION TESTS
MODULE Liver Function Tests 17 LIVER FUNCTION TESTS 17.1 INTRODUCTION Liver function tests are a group of tests done to assess the functional capacity of the liver as well as any cellular damage to the
More informationSeries 1 Case Studies Adverse Events that Represent Unanticipated Problems: Reporting Required
Welcome! This document contains three (3) series of Case Study examples that will demonstrate all four OHSU reporting categories (#1 4) as well as examples of events that are considered not reportable.
More informationRole of taxanes in the treatment of advanced NHL patients: A randomized study of 87 cases
Role of taxanes in the treatment of advanced NHL patients: A randomized study of 87 cases R. Shraddha, P.N. Pandit Radium Institute, Patna Medical College and Hospital, Patna, India Abstract NHL is a highly
More informationDate of preparation: March 2015. GL/XIF/0214/0011a(1)
Date of preparation: March 2015. GL/XIF/0214/0011a(1) 1 This educational programme is funded by a grant from Norgine. Norgine has no involvement in the development of the content, which is developed independently
More informationThe pathogenesis of hepatic encephalopathy in
Correlation between Ammonia Levels and the Severity of Hepatic Encephalopathy Janus P. Ong, MD, Anjana Aggarwal, MD, Derk Krieger, MD, Kirk A. Easley, MS, Matthew T. Karafa, MS, Frederick Van Lente, PhD,
More informationThe sooner the better
The sooner the better A guide to MARS the liver support therapy Liver failure and MARS therapy Developing acute liver failure or deteriorating from a chronic liver disease, thousands of people are enlisted
More informationA study to Evaluate PPI s effect on vitamin D levels. Rani Hanna M.D., M.S. PGY-3 Joseph Grisanti, MD
A study to Evaluate PPI s effect on vitamin D levels Rani Hanna M.D., M.S. PGY-3 Joseph Grisanti, MD The sunshine vitamin Existed over 500 million years. Prehormone, not only a vitamin. Two major sources:
More informationDrugs for MS.Drug fact box cannabis extract (Sativex) Version 1.0 Author
Version History Policy Title Drugs for MS.Drug fact box cannabis extract (Sativex) Version 1.0 Author West Midlands Commissioning Support Unit Publication Date Jan 2013 Review Date Supersedes/New (Further
More informationAlcoholic Hepatitis (Teacher s Guide)
Thomas Ormiston, M.D. Updated 5/5/15 2007-2015, SCVMC Alcoholic Hepatitis (Teacher s Guide) (30 minutes) I. Objectives Recognize the signs and symptoms of alcoholic hepatitis Understand the treatment options
More informationBACKGROUND MEDIA INFORMATION Fast facts about liver disease
BACKGROUND MEDIA INFORMATION Fast facts about liver disease Liver, or hepatic, disease comprises a wide range of complex conditions that affect the liver. Liver diseases are extremely costly in terms of
More informationPatients with liver cirrhosis produce. Enterococcus Lactic Acid Bacteria Strain SF68 and Lactulose in Hepatic Encephalopathy: a Controlled Study
The Journal ofinternational Medical Research 1987; 15: 335-343 Enterococcus Lactic Acid Bacteria Strain SF68 and Lactulose in Hepatic Encephalopathy: a Controlled Study C. Loguercio, C. Del Vecchio Blanco
More informationSponsor. Novartis Generic Drug Name. Vildagliptin. Therapeutic Area of Trial. Type 2 diabetes. Approved Indication. Investigational.
Clinical Trial Results Database Page 1 Sponsor Novartis Generic Drug Name Vildagliptin Therapeutic Area of Trial Type 2 diabetes Approved Indication Investigational Study Number CLAF237A2386 Title A single-center,
More informationIntroduction to Post marketing Drug Safety Surveillance: Pharmacovigilance in FDA/CDER
Introduction to Post marketing Drug Safety Surveillance: Pharmacovigilance in FDA/CDER LT Andrew Fine, Pharm.D., BCPS Safety Evaluator Division of Pharmacovigilance Office of Pharmacovigilance and Epidemiology
More informationTREATMENT OF HEPATIC ENCEPHALOPATHY: TARGETING THE GUT-LIVER-BRAIN AXIS
TREATMENT OF HEPATIC ENCEPHALOPATHY: TARGETING THE GUT-LIVER-BRAIN AXIS Summary of Presentations from the Norgine Sponsored Satellite Symposium, UEG Week, Berlin, Germany, 12 th 16 th October 2013 Chairperson
More informationBile Duct Diseases and Problems
Bile Duct Diseases and Problems Introduction A bile duct is a tube that carries bile between the liver and gallbladder and the intestine. Bile is a substance made by the liver that helps with digestion.
More informationFrequently Asked Questions (FAQs)
Frequently Asked Questions (FAQs) Research Rationale 1. What does PrEP stand for? There is scientific evidence that antiretroviral (anti-hiv) medications may be able to play an important role in reducing
More informationAn Investigation of Alcohol Metabolizing Enzyme Genes in Chinese Alcoholics With Pancreatitis,, Cirrhosis of Liver, and Avascular Necrosis of Hip
An Investigation of Alcohol Metabolizing Enzyme Genes in Chinese Alcoholics With Pancreatitis,, Cirrhosis of Liver, and Avascular Necrosis of Hip Joints Introduction Maezawa et al., have reported that
More informationHEPATIC ENCEPHALOPATHY; PRECIPITATING FACTORS IN PATIENTS WITH CIRRHOSIS
HEPATIC ENCEPHALOPATHY 375 ORIGINAL PROF-335 HEPATIC ENCEPHALOPATHY; PRECIPITATING FACTORS IN PATIENTS WITH CIRRHOSIS COL. DR. MANZAR ZAKARIA Classified Medical Specialist Department of Medicine DR. SYED
More informationLiver, Gallbladder, Exocrine Pancreas KNH 406
Liver, Gallbladder, Exocrine Pancreas KNH 406 2007 Thomson - Wadsworth LIVER Anatomy - functions With disease blood flow becomes obstructed Bile All bile drains into common hepatic duct Liver Bile complex
More informationElements for a Public Summary
VI.2 Elements for a Public Summary VI.2.1 Overview of Disease Epidemiology Hunter syndrome is a rare genetic disease which mainly affects males of all ethnicities. The incidence rate ranges from 0.6 to
More informationLiving With Hepatic Encephalopathy (HE)
Living With Hepatic Encephalopathy (HE) What is hepatic encephalopathy (HE)? HE is a condition that occurs in people with advanced cirrhosis or severe liver damage. The damaged liver cannot remove the
More informationADVANCE: a factorial randomised trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes
ADVANCE: a factorial randomised trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes Effects of a fixed combination of the ACE inhibitor, perindopril,
More information2. Background This drug had not previously been considered by the PBAC.
PUBLIC SUMMARY DOCUMENT Product: Ambrisentan, tablets, 5 mg and 10 mg, Volibris Sponsor: GlaxoSmithKline Australia Pty Ltd Date of PBAC Consideration: July 2009 1. Purpose of Application The submission
More informationRivaroxaban: Prescribing Guidance for the treatment of provoked venous thromboembolism (VTE)
Rivaroxaban: Prescribing Guidance for the treatment of provoked venous thromboembolism (VTE) Amber Drug Level 2 Leeds We have started your patient on rivaroxaban for the treatment of provoked VTE (deep
More informationBig Data for Population Health and Personalised Medicine through EMR Linkages
Big Data for Population Health and Personalised Medicine through EMR Linkages Zheng-Ming CHEN Professor of Epidemiology Nuffield Dept. of Population Health, University of Oxford Big Data for Health Policy
More informationINTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE. Current Step 4 version
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE THE EXTENT OF POPULATION EXPOSURE TO ASSESS CLINICAL
More informationSignificance of Serum Ascites Albumin Gradient and Ascitic Fluid Cholesterol in Classification of Ascites
ORIGINAL ARTICLE Significance of Serum Ascites Albumin Gradient and Ascitic Fluid Cholesterol in Classification of Ascites 1 B.Venugopal, 2 B.Sai Ravi Kiran, 3 G.Surya Prakash 4 E.Prabhakar Reddy ABSTRACT
More informationComplications of Chronic Liver Disease
Complications of Chronic Liver Disease By Rima A. Mohammad, Pharm.D., BCPS Reviewed by Paulina Deming, Pharm.D.; Marisel Segarra-Newnham, Pharm.D., MPH, FCCP, BCPS; and Kelly S. Bobo, Pharm.D., BCPS Learning
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationA CASE OF LIVER CIRRHOSIS & HEPATIC ENCEPHALOPATHY
A CASE OF LIVER CIRRHOSIS & HEPATIC ENCEPHALOPATHY 2 1 Mr N.N. 56 yr old male. Admitted on 22/03/02. 1 month Hx of abdominal distention, confusion, inability to concentrate and dyspnoea Grade 111. Pmx:
More informationELEMENTS FOR A PUBLIC SUMMARY. Overview of disease epidemiology. Summary of treatment benefits
VI: 2 ELEMENTS FOR A PUBLIC SUMMARY Bicalutamide (CASODEX 1 ) is a hormonal therapy anticancer agent, used for the treatment of prostate cancer. Hormones are chemical messengers that help to control the
More informationOMG my LFT s! How to Interpret and Use Them. OMG my LFT s! OMG my LFT s!
How to Interpret and Use Them René Romero, M.D. Clinical Director, Pediatric Hepatology CPG Gastroenterology, Hepatology and Nutrition Emory University School of Medicine Objectives Understand the anatomy
More informationManaging LFT s in General Practice
Managing LFT s in General Practice Sulleman Moreea FRCP(Edin Edin) ) FRCS(Glasg Glasg) Consultant Gastroenterologist/Hepatologist Bradford Hospitals Trust The normal liver Managing LFT s History and examination
More informationReport of the Veal Calf Vaccination Study with Rispoval IntraNasal (Zoetis)
Report of the Veal Calf Vaccination Study with Rispoval IntraNasal (Zoetis) Date: February 18, 2014 H. A. Vahl, H. Bekman and J. van Riel Introduction: Substantial percentages of antibiotics applied in
More informationCOMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP)
The European Agency for the Evaluation of Medicinal Products Evaluation of Medicines for Human Use London, 19 March 2003 CPMP/EWP/785/97 COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) POINTS TO CONSIDER
More informationMetabolic Syndrome with Prediabetic Factors Clinical Study Summary Concerning the Efficacy of the GC Control Natural Blood Sugar Support Supplement
CLINICALLY T E S T E D Natural Blood Sugar Metabolic Syndrome with Prediabetic Factors Clinical Study Summary Concerning the Efficacy of the GC Control Natural Blood Sugar Metabolic Syndrome with Prediabetic
More informationTreatment of Opioid Dependence: A Randomized Controlled Trial. Karen L. Sees, DO, Kevin L. Delucchi, PhD, Carmen Masson, PhD, Amy
Category: Heroin Title: Methadone Maintenance vs 180-Day psychosocially Enriched Detoxification for Treatment of Opioid Dependence: A Randomized Controlled Trial Authors: Karen L. Sees, DO, Kevin L. Delucchi,
More informationClinical Trials of Disease Modifying Treatments
MS CENTER CLINICAL RESEARCH The UCSF MS Center is an internationally recognized leader in multiple sclerosis clinical research. We conduct clinical trials involving the use of experimental treatments,
More informationPrimary Care Guidance Program: Non-Alcohol related Fatty Liver Disease (NAFLD) Guidance on Management in Primary Care
Primary Care Guidance Program: Non-Alcohol related Fatty Liver Disease (NAFLD) Guidance on Management in Primary Care This advice has been developed to help GPs with shared care of patients with Non- Alcohol
More informationRibavirin/Pegylated Interferon Combination Therapy for People with Hepatitis C
Ribavirin/Pegylated Combination Therapy for People with Hepatitis C 1. Introduction 2. What the treatment does 3. When to take it 4. What is? 5. What is interferon? 6. What is pegylated interferon? 7.
More informationHepatitis C. David Mutimer Queen Elizabeth Hospital Liver Unit Birmingham. Substance Misuse Treatment in the West Midlands. How can we reduce harm?
Hepatitis C David Mutimer Queen Elizabeth Hospital Liver Unit Birmingham Substance Misuse Treatment in the West Midlands. How can we reduce harm? Birmingham October 19 th 2007 infection HCV Natural History
More informationLong-term Results of Pegylated Interferon alfa-2a and Tenofovir for Hepatitis B
Long-term Results of Pegylated Interferon alfa-2a and Tenofovir for Hepatitis B Patrick Marcellin Viral Hepatitis Research Center Hôpital Beaujon, University of Paris France OBJECTIVES OF THERAPY IN CHRONIC
More informationHepatitis C Treatment Criteria Commercial & Minnesota Health Care Programs
Last update: February 23, 2015 Hepatitis C Treatment Criteria Commercial & Minnesota Health Care Programs Please see healthpartners.com for Medicare coverage criteria. Table of Contents 1. Harvoni 2. Sovaldi
More informationNew IDSA/AASLD Guidelines for Hepatitis C
NORTHWEST AIDS EDUCATION AND TRAINING CENTER New IDSA/AASLD Guidelines for Hepatitis C John Scott, MD, MSc Associate Professor, UW SoM Asst Director, Liver Clinic, Harborview Medical Center Presentation
More informationSymptomspesifikke probiotikum. Linda Mulder, MSc. Vårseminaret 2014
Linda Mulder, MSc. Vårseminaret 2014 Content Background on probiotics Intestinal microbiota & health on 3 levels Indication-specific probiotics Strain-specific characteristics Monostrain vs. multispecies
More informationPRIOR AUTHORIZATION PROTOCOL FOR HEPATITIS C TREATMENT
PRIOR AUTHORIZATION PROTOCOL FOR HEPATITIS C TREATMENT HARVONI (90mg ledipasvir/400mg sofosbuvir): tablet (PREFERRED AGENT) SOVALDI (sofosbuvir ): 400mg tablets (PREFERRED AGENT ) OLYSIO (simeprivir) PEG-INTRON
More informationProbiotic for the Treatment of Minimal Hepatic Encephalopathy: Preliminary Report ABSTRACT
Original Article Issariyakulkarn N, et al. THAI J GASTROENTEROL 2010 Vol. 11 No. 3 Sept. - Dec. 2010 129 Issariyakulkarn N Sanpajit T Surangsrirat S ABSTRACT Objectives: Minimal hepatic encephalopathy
More informationDepartment of Veterans Affairs VHA HANDBOOK 1140.5. Washington, DC 20420 March 1, 2005 COMMUNITY HOSPICE CARE: REFERRAL AND PURCHASE PROCEDURES
Department of Veterans Affairs VHA HANDBOOK 1140.5 Veterans Health Administration Transmittal Sheet Washington, DC 20420 March 1, 2005 COMMUNITY HOSPICE CARE: REFERRAL AND PURCHASE PROCEDURES 1. REASON
More informationNon-alcoholic fatty liver disease: Prognosis and Treatment
Non-alcoholic fatty liver disease: Prognosis and Treatment Zachary Henry, M.D. Assistant Professor UVA Gastroenterology & Hepatology October 28, 2015 Overview Case Presentation Prognosis Effects of fibrosis
More informationHEPATITIS WEB STUDY Acute Hepatitis C Virus Infection: Epidemiology, Clinical Features, and Diagnosis
HEPATITIS WEB STUDY Acute C Virus Infection: Epidemiology, Clinical Features, and Diagnosis H. Nina Kim, MD Assistant Professor of Medicine Division of Infectious Diseases University of Washington School
More informationMedication Policy Manual. Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012
Medication Policy Manual Policy No: dru283 Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012 Committee Approval Date: December 12, 2014 Next Review Date: December 2015 Effective Date: January
More information